Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB

Nature Medicine

Volumn 8, Issue 4, 2002, Pages 343-348

  Ye, Zhengmao ^a,b   Hellström, Ingegerd ^a   Hayden Ledbetter, Martha ^a   Dahlin, Amber ^a   Ledbetter, Jeffrey A ^a   Hellström, Karl Erik ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD137 ANTIGEN; HLA ANTIGEN CLASS 1; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; RECOMBINANT ANTIBODY;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOGENICITY; METASTASIS INHIBITION; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY; VACCINE PRODUCTION;

ANIMALS; ANTIBODY SPECIFICITY; ANTIGENS, CD; ANTIGENS, CD137; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; FEMALE; GENE THERAPY; HUMANS; IMMUNOGLOBULIN FRAGMENTS; INTERFERON TYPE II; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C3H; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR; TH1 CELLS; TRANSFECTION;

ANIMALIA;

EID: 0036104604     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0402-343     Document Type: Article

References (35)

1. Adoptive T cell therapy of tumors: Mechanisms operative in the recognition and elimination of tumor cells
2. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes
3. Immunity to oncogenic proteins
4. Cancer vaccines: A road map for the next decade
5. Tumor antigens recognized by T cells
6. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
7. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
8. Tumor-induced immune dysfunction
9. + regulatory T cells is mediated by cell surface-bound transforming growth factor β
10. Enhancement of antitumor immunity by CTLA-4 blockade
11. + T cells
12. Immune-mediated eradication of tumors through the blockade of transforming growth factor-β signaling in T cells
13. Therapeutic vaccination for cancer
14. Costimulation by CD28 scFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen
15. + T cell proliferation and lead to the amplification in vivo of cytotoxic T cell responses
16. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors
17. Amplification of tumor immunity by gene transfer of the co-stimulatory 4-1BB ligand: Synergy with the CD28 co-stimulatory pathway
18. Surface expression of CD28 single chain Fv for costimulation by tumor cells
19. Costimulation by CD28 scFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen
20. Biological and experimental consequences of the zonal composition of solid tumors
21. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity
22. Loss of HLA class I antigens by melanoma cells: Molecular mechanisms, functional significance and clinical relevance
23. - dendritic cells cross-prime cytotoxic T cells in vivo
24. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
25. The role of B7-2 (CD86) in tumor immunity
26. Costimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors
27. + T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma
28. Express yourself or die: Peptides, MHC molecules, and NK cells
29. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells
30. Rapid and reliable cloning of antibody variable regions and generation of recombinant single chain antibody fragments
31. Subcellular localization of CD80 receptors is dependent on an intact cytoplasmic tail and is required for CD28-dependent T cell costimulation
32. Two regions in the CD80 cytoplasmic tail regulate CD80 redistribution and T cell costimulation
33. + T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen
34. Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy